About Us /
Board of Directors
Jim Broderick, M.D., Co-Founder and Chairman
Jim Broderick is a Partner on the Morgenthaler Life Sciences Team and invests in companies developing innovative therapeutic products in the biotech and medical device industries. Jim is a co-founder of Ra and serves as Chairman of the Board of Directors. Jim was the founding CEO and serves as Board member at SetPoint Medical, a co-founder and board member at Promedior Pharmaceuticals, and a board member of OncoMed Pharmaceuticals and Spine Wave.
Jim trained as a physician and an engineer. He is a graduate of the Massachusetts Institute of Technology (Bachelors in mechanical engineering) and University of Massachusetts (Doctor of Medicine). Jim was a member of the Kauffman Fellows Program and a consultant at Mercer Management Consulting. He performed his medical residency at Duke University Medical Center.
Ed Mathers, New Enterprise Associates
Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Intarcia, Liquidia Technologies, Plexxikon, Ra Pharmaceuticals, Rhythm Pharmaceuticals, and Satori Pharmaceuticals. Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the Company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the Company’s corporate and business development activities and led the Company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. Ed currently sits on the boards of directors of Plexxikon Inc., Satori Pharmaceuticals, Intarcia, Rhythm Pharmaceuticals and Liquidia. He earned his bachelor's degree in chemistry from North Carolina State University.
Lauren Silverman, Ph.D., Novartis Venture Funds
Lauren Silverman is a Managing Director of the Novartis Option Fund. Prior to joining the Option Fund, she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology at Cadus Pharmaceuticals, where she was a founding scientist. She is the author of multiple scientific publications and several issued patents and serves on the Business Advisory Board of the Epilepsy Research Foundation’s Epilepsy Therapy Project and National Cancer Institute’s SBIR review panel. Lauren currently serves on the Board of Directors of Anchor Therapeutics, Proteostasis Therapeutics, Cequent Pharmaceuticals, Viamet Pharmaceuticals, and Pulmatrix Inc. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah.
Doug Treco, Ph.D., Co-Founder, President and CEO
Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his Ph.D. in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.